FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313488165> ?p ?o ?g. }

• W4313488165 endingPage "785" @default.
• W4313488165 startingPage "769" @default.
• W4313488165 abstract "ABSTRACTIntroduction CYP2D6 contributes to the metabolism of approximately 20–25% of drugs. However, CYP2D6 is highly polymorphic and different alleles can lead to impacts ranging from null to increase in activity. Moreover, there are commonly used drugs that potently inhibit the CYP2D6, thus causing ‘phenoconversion’ which can convert the genotypic normal metabolizer into phenotypic poor metabolizer. Despite growing literature on the clinical implications of non-normal CYP2D6 genotype and phenoconversion on patient-related outcomes, implementation of CYP2D6 pharmacogenetics and phenoconversion to guide prescribing is rare. This review focuses on providing the clinical importance of CYP2D6 pharmacogenetics and phenoconversion in precision medicine and summarizes the challenges and approaches to implement these into clinical practice.Areas covered A literature search was performed using PubMed and clinical studies documenting the effects of CYP2D6 genotypes and/or CYP2D6 inhibitors on pharmacokinetics, pharmacodynamics or treatment outcomes of CYP2D6-metabolized drugs, and studies on implementation challenges and approaches.Expert opinion Considering the extent and impact of genetic polymorphisms of CYP2D6, phenoconversion by the comedications, and contribution of CYP2D6 in drug metabolism, CYP2D6 pharmacogenetics is essential to ensure drug safety and efficacy. Utilization of proper guidelines incorporating both CYP2D6 pharmacogenetics and phenoconversion in clinical care assists in optimizing drug therapy.KEYWORDS: CYP2D6phenoconversionenzyme inhibitionpharmacogeneticsopioidsantidepressantstamoxifenpersonalized medicineprecision medicinedrug–drug interactiondrug–drug-gene interaction Article highlights CYP2D6 is estimated to contribute to the metabolism of approximately 20–25% of drugs. CYP2D6 is involved not only in metabolizing active drugs into its inactive metabolites (e.g. paroxetine, aripiprazole) but also in metabolizing inactive drugs into its active metabolite including (e.g. codeine, tamoxifen). Therefore, the metabolic activity of CYP2D6 is associated with adverse drug reactions or drug ineffectiveness.The gene encoding CYP2D6 is highly polymorphic, and around 100 alleles of CYP2D6 with different impact on function of the encoded protein have been identified. An activity score is given to a specific allele of CYP2D6 and summing the activity scores of the two (or more) alleles leads to the diplotype activity score. Using the diplotype score, genotypic phenotype of CYP2D6 is estimated, with the resulting phenotypes including poor metabolizer (PM), intermediate metabolizer (IM), normal metabolizer (NM), and ultra-rapid metabolizer (UM).Strong (e.g. paroxetine, bupropion) and moderate (e.g. duloxetine, sertraline) inhibitors can also decrease the CYP2D6 activity, phenoconverting the genotypic NMs or UMs into phenotypic PMs or IMs. So, concomitant use of those drugs cannot be overlooked while predicting the CYP2D6 phenotype. Moreover, data indicate that up to 20–70% of the patients who are on CYP2D6 metabolized drugs are at risk of CYP2D6 phenoconversion by concomitant medications.It is important to adjust the activity score of CYP2D6 based on the use of CYP2D6 inhibitors. If the individual is taking one of the strong or moderate inhibitors concomitantly, then the genotype-based activity score should be multiplied by 0 or 0.5, respectively. Then, the actual clinical phenotype can be estimated based on the adjusted activity score.Pharmacogenetic-based drug therapy guidelines have been developed for at least 50 CYP2D6-metabolized drugs based on the activity of CYP2D6. Considering the importance of phenoconversion, Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines suggest incorporating the effects of CYP2D6 inhibitors while calculating the activity score of CYP2D6 for CYP2D6 metabolized opioids, tricyclic antidepressants, tamoxifen, and atomoxetine.There are many challenges to implementing the use of CYP2D6 pharmacogenetics and phenoconversion to guide prescribing. These include proper interpretation of genotype-based phenotype from CYP2D6 alleles or activity score, adjustment of phenotype considering the concomitant administration of CYP2D6 inhibitor medications, routinely checking of concomitant medications for phenotype adjustment, reimbursement of genetic testing costs, proper training of the clinicians, etc.This box summarizes key points contained in the article.Declaration of interestThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.Reviewer disclosuresPeer reviewers on this manuscript have no relevant financial or other relationships to disclose.Additional informationFundingThis paper was funded by the National Institutes of Health (U01-HG007269) to JA Johnson and an American College of Clinical Pharmacy Foundation Futures Grant to NA Nahid." @default.
• W4313488165 created "2023-01-06" @default.
• W4313488165 creator A5034467370 @default.
• W4313488165 creator A5088669682 @default.
• W4313488165 date "2022-11-02" @default.
• W4313488165 modified "2023-09-30" @default.
• W4313488165 title "CYP2D6 pharmacogenetics and phenoconversion in personalized medicine" @default.
• W4313488165 cites W1495126388 @default.
• W4313488165 cites W1517252188 @default.
• W4313488165 cites W1547426779 @default.
• W4313488165 cites W1946623496 @default.
• W4313488165 cites W1954706707 @default.
• W4313488165 cites W1964142218 @default.
• W4313488165 cites W1966355764 @default.
• W4313488165 cites W1968635545 @default.
• W4313488165 cites W1968814844 @default.
• W4313488165 cites W1969692023 @default.
• W4313488165 cites W1973178798 @default.
• W4313488165 cites W1976578019 @default.
• W4313488165 cites W1976578059 @default.
• W4313488165 cites W1977093684 @default.
• W4313488165 cites W1977931991 @default.
• W4313488165 cites W1978470279 @default.
• W4313488165 cites W1978689262 @default.
• W4313488165 cites W1980471105 @default.
• W4313488165 cites W1981046943 @default.
• W4313488165 cites W1981367166 @default.
• W4313488165 cites W1981731045 @default.
• W4313488165 cites W1985327494 @default.
• W4313488165 cites W1985687780 @default.
• W4313488165 cites W1988235147 @default.
• W4313488165 cites W1993682664 @default.
• W4313488165 cites W1994171421 @default.
• W4313488165 cites W1994311873 @default.
• W4313488165 cites W1996605119 @default.
• W4313488165 cites W1997069340 @default.
• W4313488165 cites W1997530992 @default.
• W4313488165 cites W1997607568 @default.
• W4313488165 cites W1997656392 @default.
• W4313488165 cites W1998001503 @default.
• W4313488165 cites W1998968541 @default.
• W4313488165 cites W1999720233 @default.
• W4313488165 cites W2000123777 @default.
• W4313488165 cites W2000595776 @default.
• W4313488165 cites W2002028786 @default.
• W4313488165 cites W2002622298 @default.
• W4313488165 cites W2004561313 @default.
• W4313488165 cites W2004848360 @default.
• W4313488165 cites W2012156333 @default.
• W4313488165 cites W2012723101 @default.
• W4313488165 cites W2014756391 @default.
• W4313488165 cites W2015708008 @default.
• W4313488165 cites W2018608742 @default.
• W4313488165 cites W2021141873 @default.
• W4313488165 cites W2024238924 @default.
• W4313488165 cites W2026378497 @default.
• W4313488165 cites W2026751993 @default.
• W4313488165 cites W2029549183 @default.
• W4313488165 cites W2029706261 @default.
• W4313488165 cites W2032594110 @default.
• W4313488165 cites W2033026546 @default.
• W4313488165 cites W2034839664 @default.
• W4313488165 cites W2039848755 @default.
• W4313488165 cites W2042056993 @default.
• W4313488165 cites W2042371909 @default.
• W4313488165 cites W2043527756 @default.
• W4313488165 cites W2045273410 @default.
• W4313488165 cites W2047503441 @default.
• W4313488165 cites W2052278960 @default.
• W4313488165 cites W2058167269 @default.
• W4313488165 cites W2062250286 @default.
• W4313488165 cites W2063017492 @default.
• W4313488165 cites W2069624475 @default.
• W4313488165 cites W2073973349 @default.
• W4313488165 cites W2075551544 @default.
• W4313488165 cites W2076741971 @default.
• W4313488165 cites W2079864891 @default.
• W4313488165 cites W2084899864 @default.
• W4313488165 cites W2086903705 @default.
• W4313488165 cites W2090628258 @default.
• W4313488165 cites W2092510009 @default.
• W4313488165 cites W2095575057 @default.
• W4313488165 cites W2098768607 @default.
• W4313488165 cites W2104058573 @default.
• W4313488165 cites W2106444498 @default.
• W4313488165 cites W2113430663 @default.
• W4313488165 cites W2117436750 @default.
• W4313488165 cites W2119132796 @default.
• W4313488165 cites W2120036296 @default.
• W4313488165 cites W2120384798 @default.
• W4313488165 cites W2122781091 @default.
• W4313488165 cites W2123875644 @default.
• W4313488165 cites W2124448589 @default.
• W4313488165 cites W2125049605 @default.
• W4313488165 cites W2125579275 @default.
• W4313488165 cites W2125986742 @default.
• W4313488165 cites W2130112316 @default.
• W4313488165 cites W2130377362 @default.

• next